List of the latest selling price information of Enasidenib in 2025

Enasidenib is a targeted drug for the treatment of specific types of hematological tumors. Its original drug has not yet been officially launched in the domestic market by 2025. Therefore, it is not covered by medical insurance in mainland China, which has a certain impact on the cost of medication for patients. Since there are no formal domestic sales channels, patients who need to use ensidipine can only purchase it through overseas channels, and the price is relatively high.

In overseas markets, the original drug of ensidipine is relatively expensive. Common specifications include 50mg30 tablets and 100mg30 tablets. Each box may be sold for about 300,000 yuan, and the specific price will change due to exchange rate fluctuations. Such high prices put some patients under greater financial pressure in treatment options, especially those who require long-term medication.

It is worth noting that in order to reduce the cost of treatment, generic versions of ensidipine have also appeared in overseas markets. These generic drugs are usually produced by manufacturers such as Laos Lucius Pharmaceutical Factory. The specifications are 50mg*30 tablets, and the price per box is about more than 1,000 yuan. Although the price has been significantly reduced, its medicinal ingredients are basically the same as those of the original drug, which can provide patients with effective treatment options.

Overall, ensidipine is still not on the market in China, with a relatively high price and no medical insurance support. If patients need to use it, it is recommended to purchase generic drugs through regular overseas channels to reduce the financial burden. At the same time, they should use drugs rationally under the guidance of professional doctors to ensure the safety and effectiveness of treatment.

Reference materials:https://www.idhifa.com/